[go: up one dir, main page]

BR0007936A - Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno - Google Patents

Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno

Info

Publication number
BR0007936A
BR0007936A BR0007936-7A BR0007936A BR0007936A BR 0007936 A BR0007936 A BR 0007936A BR 0007936 A BR0007936 A BR 0007936A BR 0007936 A BR0007936 A BR 0007936A
Authority
BR
Brazil
Prior art keywords
antigen
formulation
compound
stimulate
immune response
Prior art date
Application number
BR0007936-7A
Other languages
English (en)
Other versions
BR0007936B1 (pt
BRPI0007936B8 (pt
Inventor
Lynn D Hawkins
Sally T Ishizaka
Michael Lewis
Pamela Mcguiness
Anneliese Nault
Jeffrey Rose
Daniel P Rossignol
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of BR0007936A publication Critical patent/BR0007936A/pt
Publication of BR0007936B1 publication Critical patent/BR0007936B1/pt
Publication of BRPI0007936B8 publication Critical patent/BRPI0007936B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, FORMULAçãO ADJUVANTE IMUNOLóGICA, FORMULAçãO DE VACINA, E, PROCESSO PARA ESTIMULAR UMA RESPOSTA IMUNE A UM ANTìGENO". A presente invenção é dirigida a novos compostos que funcionam como adjuvantes imunológicos quando co-administrados com antígenos como vacinas para doenças bacterianas e virais, a novas formulações adjuvantes que incluem, pelo menos, um dos compostos adjuvantes da invenção, a novas composições imunoestimulatórias que compreendem um antígeno e pelo menos um dos compostos adjuvantes da invenção, e a processos para a imunização de um animal por co-admistração de um composto da invenção com um antígeno contra o qual o animal deve ser imunizado.
BRPI0007936A 1999-02-01 2000-02-01 composto, formulação adjuvante imunológica, e formulação de vacina. BRPI0007936B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11813199P 1999-02-01 1999-02-01
US60/118,131 1999-02-01
PCT/US2000/002755 WO2000044758A1 (en) 1999-02-01 2000-02-01 Immunological adjuvant compound

Publications (3)

Publication Number Publication Date
BR0007936A true BR0007936A (pt) 2002-04-09
BR0007936B1 BR0007936B1 (pt) 2015-03-10
BRPI0007936B8 BRPI0007936B8 (pt) 2021-05-25

Family

ID=22376670

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0007936A BRPI0007936B8 (pt) 1999-02-01 2000-02-01 composto, formulação adjuvante imunológica, e formulação de vacina.

Country Status (21)

Country Link
US (1) US6290973B1 (pt)
EP (2) EP1439184B1 (pt)
JP (1) JP4698027B2 (pt)
KR (1) KR100711561B1 (pt)
AT (2) ATE269341T1 (pt)
AU (2) AU768574B2 (pt)
BR (1) BRPI0007936B8 (pt)
CA (1) CA2361582C (pt)
DE (2) DE60011571T2 (pt)
DK (1) DK1147117T3 (pt)
ES (2) ES2347428T3 (pt)
FI (1) FI120689B (pt)
HK (1) HK1043132B (pt)
HU (1) HU226869B1 (pt)
IL (3) IL144671A0 (pt)
MX (1) MXPA01007760A (pt)
NO (1) NO329111B1 (pt)
NZ (1) NZ513259A (pt)
PT (1) PT1147117E (pt)
WO (1) WO2000044758A1 (pt)
ZA (1) ZA200106487B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
JP4230765B2 (ja) 2000-07-31 2009-02-25 エーザイ株式会社 免疫アジュバント化合物、組成物、およびその使用方法
SI21352A (sl) 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
EP2289524A1 (en) * 2001-03-08 2011-03-02 The Trustees Of The University Of Pennsylvania Facially amphiphillic polymers as anti-infective agents
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
EP1513853A2 (en) * 2002-05-24 2005-03-16 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
JP3900343B2 (ja) * 2002-09-05 2007-04-04 株式会社トリケミカル研究所 （ｒｏ）（ｒ’ｏ）（ｒ’’ｏ）ｍ＝ｏの製造方法
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
EP2471525A3 (en) * 2003-03-17 2012-12-12 The Trustees Of The University Of Pennsylvania Facially amphiphllic polymers and oligomers and uses thereof
ATE437633T2 (de) 2003-06-02 2009-08-15 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
EP1697389A4 (en) * 2003-10-24 2008-12-24 Eisai R&D Man Co Ltd COMPOUNDS AND METHODS FOR TREATING ILLNESS AND SUFFERING TOLL-LIKE RECEPTOR 2 RELATED DISORDERS
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
CN1922133A (zh) 2004-01-23 2007-02-28 宾夕法尼亚州大学理事会 表面两亲性聚芳基和聚芳基炔基聚合物和低聚物及其用途
WO2006093813A2 (en) * 2005-02-25 2006-09-08 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA et al. Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
KR101294455B1 (ko) 2005-06-30 2013-08-07 에자이 알앤드디 매니지먼트 가부시키가이샤 면역 아쥬반트 제조용 화합물
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducción de respuestas inmunes
CA2708148C (en) * 2007-12-18 2015-07-07 Eisai R&D Management Co., Ltd. Reagents and methods for the beta-keto amide synthesis of a synthetic precursor to immunological adjuvant e6020
US9114098B2 (en) 2008-06-04 2015-08-25 The Chemo-Sero-Therapeutic Research Institute Method for using inactivated Japanese encephalitis virus particles as adjuvant
WO2013043580A2 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
EP2844303B1 (en) * 2012-05-03 2021-09-15 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same
WO2014144777A2 (en) * 2013-03-15 2014-09-18 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
US11013711B2 (en) 2016-06-10 2021-05-25 Beth Israel Deaconess Medical Center, Inc. Fatty acid esters of hydroxy fatty acids (FAHFAs) for use in the treatment of type 1 diabetes
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
CN113307824B (zh) 2021-04-26 2022-05-27 浙江大学 一种双亲性材料及其在制备脂质体中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004672A1 (en) * 1991-09-11 1993-03-18 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5904925A (en) * 1993-12-09 1999-05-18 Exner; Heinrich Adjuvant for antigens, and process for making
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof

Also Published As

Publication number Publication date
DE60011571T2 (de) 2005-08-18
KR100711561B1 (ko) 2007-04-27
WO2000044758A1 (en) 2000-08-03
HK1043132B (en) 2005-04-01
HK1070372A1 (en) 2005-06-17
AU2004201147B2 (en) 2008-04-03
DE60011571D1 (de) 2004-07-22
HUP0105473A3 (en) 2003-11-28
FI120689B (fi) 2010-01-29
HU226869B1 (en) 2010-01-28
MXPA01007760A (es) 2003-06-24
DE60044570D1 (de) 2010-07-29
NO20013749L (no) 2001-09-25
JP4698027B2 (ja) 2011-06-08
JP2002535411A (ja) 2002-10-22
ATE269341T1 (de) 2004-07-15
AU2004201147A1 (en) 2004-04-22
KR20010101912A (ko) 2001-11-15
US6290973B1 (en) 2001-09-18
EP1147117A1 (en) 2001-10-24
NO329111B1 (no) 2010-08-30
BR0007936B1 (pt) 2015-03-10
IL144671A0 (en) 2002-05-23
ATE471328T1 (de) 2010-07-15
AU2867500A (en) 2000-08-18
CA2361582A1 (en) 2000-08-03
NZ513259A (en) 2004-05-28
CA2361582C (en) 2010-04-06
IL144671A (en) 2006-07-05
HK1043132A1 (en) 2002-09-06
FI20011593L (fi) 2001-07-31
AU768574B2 (en) 2003-12-18
ZA200106487B (en) 2002-08-07
BRPI0007936B8 (pt) 2021-05-25
DK1147117T3 (da) 2004-10-25
EP1439184A1 (en) 2004-07-21
EP1147117B1 (en) 2004-06-16
IL174413A0 (en) 2009-02-11
EP1439184B1 (en) 2010-06-16
ES2223464T3 (es) 2005-03-01
ES2347428T3 (es) 2010-10-29
PT1147117E (pt) 2004-10-29
HUP0105473A2 (hu) 2002-04-29
NO20013749D0 (no) 2001-07-31

Similar Documents

Publication Publication Date Title
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
BR0212556A (pt) interleucina-12 como um adjuvante de vacina veterinária
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
EA200900024A1 (ru) Противогриппозная вакцина
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
NZ733383A (en) Oil-based adjuvants
ATE309821T1 (de) Influenzavirus-impfstoffzusammensetzung
IL130075A0 (en) A vaccine for eliciting an immune response to an antigen in an animal
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
BR9106601A (pt) Adjustante de vacina e processo de obter aumento da resposta imunologica a um antigeno em um ser humano ou animal
EA200800917A1 (ru) Адъюванты для вакцин
DK0626008T3 (da) Vaccine, der som en adjuvans indeholder acemannan
HUP0104125A2 (hu) Eljárás szárnyasok intradermális immunizálására inaktivált vakcinákkal
IL122829A0 (en) Isolated strains of staphylococcus aureus and vaccines manufactured therefrom
AR111910A2 (es) Composición inmunogénica que comprende una formulación de adyuvante, composición de vacuna, procedimiento, usos, métodos
WO2005041890A3 (en) Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EISAI RANDD MANAGEMENT CO., LTD. (JP)

Free format text: TRANSFERIDO DE: EISAI CO. LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/02/2020

B15V Prolongation of time limit allowed